Form 8-K · Current Report · Filed 2026-08-05
Revolution Medicines Files NDA for Daraxonrasib and Receives Breakthrough Therapy Designation
Revolution Medicines, Inc. announced its financial results for the quarter ended June 30, 2026, and provided an update on corporate progress. The company reported that the U.S. FDA accepted its New Drug Application (NDA) for daraxonrasib for the treatment of previously treated metastatic pancreatic cancer. Additionally, the FDA granted Breakthrough Therapy Designation to daraxonrasib for certain patients with previously treated metastatic RAS mutant non-small cell lung cancer. The company also achieved U.S. commercial launch readiness and began submissions to the European Medicines Agency under a new phased review process. Revolution Medicines continues to advance its broad RAS-targeted portfolio in non-small cell lung cancer and pancreatic cancer.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0001193125-26-335039
- CIK
- 0001628171
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$193.46
Since filing
+0.0%
Latest close
$193.46
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, RVMD insiders reported 17 Form 4 transactions — net selling of $3.9M.
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.